Thrombin activatable fibrinolysis inhibitor (TAFI), a novel regulator of coagulation and fibrinolysis, was discovered recently. The activated TAFI (TAFIa) makes fibrinolysin lose its action sites with fibrin, and thus exerts its fibrinolytic inhibition and promotes thrombosis. Making a thorough study of TAFI may provide a new option for the treatment of ischemic cerebrovascular disease.

To increase the dissolution rate and extent of valsartan, valsartan nanosuspensions have been prepared. Controlled precipitation assisted with sonication is utilized to prepare valsartan nanosuspensions, the concentration of the drug, stabilizer and costablizer had a great effect on the stability of the preparation according to the pre-experiment. So the method of central composite design-response surface is used to optimize the prescription based on the above three factors and the particle size as the response value. The software Origin 8.0 is used to draw the view of the three-dimensional effects and 2D contour map, to get the optimal prescription area. Valsartan nanosuspensions were prepared. The mean diameter and zeta potential are about 216.6 nm and -57.7 mV, respectively. Compared with the microsuspensions and commercial preparation, the dissolution of valsartan nanosuspensions was faster and the bioavailability can be enhanced to some extent.